Advice
Following a full submission
oxycodone/naloxone prolonged release tablets (Targinact) are not recommended for use within NHS Scotland for the treatment of severe pain which can be adequately managed only with opioid analgesics.
The addition of naloxone to oxycodone did not impair analgesia and improved bowel function when patients were not receiving regular laxative therapy. However the clinical benefit in patients receiving regular laxative therapy is uncertain and the manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Download detailed advice92KB (PDF)
Medicine details
- Medicine name:
- oxycodone / naloxone (Targinact)
- SMC ID:
- 541/09
- Indication:
- Severe pain which can be adequately managed only with opioid analgesics. Naloxone is added to counteract opioid-induced constipation.
- Pharmaceutical company
- Napp Pharmaceuticals Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 09 March 2009